Fotemustine

Fotemustine

Fotemustine
Systematic (IUPAC) name
(RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}
ethyl)phosphonate
Clinical data
AHFS/Drugs.com
Identifiers
CAS Registry Number  N
ATC code L01
PubChem CID:
DrugBank  N
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  Y
Chemical data
Formula C9H19ClN3O5P
Molecular mass 315.691 g/mol
 N   

Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study[1] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

External links

  1. ^ Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study" 22 (6). pp. 1118–25.